Unfortunately, we do have to hope for a helpful Q&A, as Missling is often not forthcoming in his scripted overviews. IR will hopefully facilitate an adequately long Q&A session. Mayo has a good list of appropriate questions, nothing silly or insider-restricted. Whether he can get them adequately answered, we'll see. Tom Bishop may also be on the Q&A, but he's ineffective and often befuddled or incoherent.
Given that a KOL told Missling the OLE could replace a confirmatory trial, one surely would expect it was part of the package.
I would like to hear Missling's explain where that KOL nonsense came from and if that really was why Anavex did not initiate the confirmatory trial as originally stated.
Market Data 
Markets 
AI
